MedPath

Royal United Hospitals Bath Join Study on Milvexian for Stroke Risk Reduction

• The Royal United Hospitals (RUH) Bath NHS Foundation Trust is participating in the Librexia study to evaluate Milvexian's efficacy in reducing recurrent ischaemic stroke risk. • Participants, aged 40 and above, who have experienced an ischaemic stroke or transient ischaemic attack within 48 hours are eligible for the trial. • Milvexian, an anticoagulant, is being tested against a placebo, alongside standard medications, to assess its impact on blood clot formation and stroke prevention. • The study involves regular assessments at the RUH, including blood tests and liver/kidney function tests, every 13 weeks for participating patients.

The Royal United Hospitals (RUH) Bath NHS Foundation Trust is now a participant in the Librexia study, a clinical trial investigating the potential of Milvexian, a novel anticoagulant, to lower the risk of recurrent ischaemic strokes. This study aims to determine if Milvexian can offer enhanced protection against future stroke events in patients who have recently experienced an ischaemic stroke or transient ischaemic attack (TIA).

Study Details and Patient Eligibility

The Librexia study is actively seeking volunteers who are at least 40 years old and have been admitted to the Royal United Hospitals within 48 hours of experiencing an ischaemic stroke or TIA. Ischaemic strokes occur when a blockage disrupts blood flow to the brain, leading to the death of brain cells and potentially causing speech and visual disturbances, as well as numbness or weakness in the limbs.
Kelly Spencer, head of research operations at the RUH, expressed enthusiasm about the hospital's involvement in the study, highlighting its potential to yield "a really positive outcome" for stroke patients.

Milvexian's Mechanism and Trial Design

Milvexian functions by thinning the blood, thereby reducing the likelihood of blood clots forming and causing further strokes. Participants in the study will be randomly assigned to receive either Milvexian or a placebo, in addition to the standard medications prescribed by their physicians. The trial involves regular follow-up appointments at the RUH every 13 weeks, during which patients will undergo comprehensive assessments, including blood tests and evaluations of liver and kidney function.

Significance of the Research

Ms. Spencer emphasized the RUH's dedication to research and its role in supporting crucial medical trials. She stated that studies like Librexia reflect the hospital's ongoing commitment to improving patient care through innovative treatments and research initiatives. The results of this study could significantly impact the management of stroke patients and potentially reduce the burden of recurrent strokes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Stroke Trial Tests Innovative Device to Combat Arm Weakness

A pioneering trial led by the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust is testing a portable, pacemaker-like device aimed at helping stroke survivors regain arm strength. The device, which delivers electrical pulses to damaged brain areas, could significantly improve hand and arm function, offering a new hope for those affected by stroke-induced arm weakness.

Bioxodes Advances BIOX-101 for Intracerebral Hemorrhage Treatment with New Funding and Clinical Milestones

Bioxodes secured €2.7 million in Series A extension funding to advance BIOX-101, a novel therapy for intracerebral hemorrhage (ICH).
The funding supports the completion of the BIRCH Phase 2a trial and preparations for a Phase 2b trial of BIOX-101 in ICH.

Velocity Clinical Research Enrolls Patients for Trials on Diabetes, Obesity, and Cardiovascular Health

Velocity Clinical Research is actively recruiting volunteers for clinical trials focusing on prevalent health conditions like high blood pressure, high cholesterol, diabetes, and weight loss.
The trials include studies on GLP-1 medications, available in both injectable and oral forms, which aid in weight management by reducing hunger and improving insulin secretion.

CAVALIER Trial: Early Intervention for Trauma Patients with Calcium and Vasopressin

Hennepin Healthcare is seeking approval to enroll trauma patients in the CAVALIER trial without prior consent, focusing on early blood loss treatment.
The CAVALIER trial investigates whether administering calcium and vasopressin earlier improves survival rates in trauma patients.

Clinical Trial Underway for Novel RSV and hMPV Vaccine in Older Adults

A Phase I clinical trial is recruiting older adults to assess the safety and immunogenicity of a new vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
The vaccine candidate, developed by Vicebio using the University of Queensland's molecular clamp technology, aims to reduce the burden of respiratory illnesses in vulnerable populations.

Hennepin Healthcare Seeks Exception for Trauma Study on Blood Loss Treatment

Hennepin Healthcare is seeking an exception to enroll unconscious trauma patients in a clinical trial without prior consent to study early interventions for blood loss.
The study will investigate whether early administration of calcium and vasopressin, compared to a placebo, improves survival rates in trauma patients.

Shuttle Pharma's Ropidoxuridine Phase 2 Trial Expands for Glioblastoma Treatment

Shuttle Pharma expands its Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with the first patient dosed at UVA Cancer Center.
The trial includes 40 patients initially, randomized to two doses, followed by 14 more at the optimal dose, targeting IDH wild-type, methylation-negative glioblastoma.

UConn Stroke Drug Advances Towards Clinical Trials with NIH Grant

UConn's experimental small-molecule drug has shown promise in reducing damage and restoring function after stroke in animal models.
A follow-up NIH grant of over $2 million will further advance testing of the anti-inflammatory therapy that targets the P2X4 receptor.

Librexia Program Aims for Inclusive Cardiovascular Clinical Trials

The Librexia program is a Phase 3 clinical trial focusing on novel treatments for blood clotting diseases, including acute coronary syndrome and atrial fibrillation.
The trial actively recruits women and people of color to ensure inclusive and equitable results relevant to all patient populations.

Basking Biosciences Initiates Phase II Trial of BB-031 for Acute Ischemic Stroke

Basking Biosciences has dosed the first subject in its Phase II RAISE trial evaluating BB-031 for acute ischemic stroke (AIS).
The trial is a multicenter, randomized, placebo-controlled, double-blinded study assessing safety, tolerability, and preliminary efficacy of BB-031.

Reference News

[1]
Bath hospital needs volunteers for stroke drug study - BBC
bbc.com · Nov 2, 2024

RUH Bath NHS Foundation Trust seeks volunteers for Librexia study on Milvexian, an anticoagulant to reduce ischaemic str...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy